TipRanks
Cantargia AB (DE:7V3)
FRANKFURT:7V3
Germany Market
7V3
Cantargia AB
RESEARCH TOOLSreports

Cantargia AB (7V3) Stock News & Sentiment

3 Followers
Cantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer
Premium
Company Announcements
Cantargia Preclinical Data Back Nadunolimab–RAS Inhibitor Combo in Aggressive Pancreatic Cancer
5d ago
Cantargia Ramps Up Investor Outreach with Series of September Conferences
Premium
Company Announcements
Cantargia Ramps Up Investor Outreach with Series of September Conferences
1M ago
Cantargia Maintains Buy Rating as Strategic Focus and Upcoming Nadunolimab Catalysts Offset Cut in Price Target to SEK12
Premium
Ratings
Cantargia Maintains Buy Rating as Strategic Focus and Upcoming Nadunolimab Catalysts Offset Cut in Price Target to SEK12
2M ago
Cantargia details pipeline and financials in H1 2026 interim report
Premium
Company Announcements
Cantargia details pipeline and financials in H1 2026 interim report
2M ago
7V3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
7V3 Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Cantargia schedules Q2 2026 results release and investor conference call
Premium
Company Announcements
Cantargia schedules Q2 2026 results release and investor conference call
2M ago
Cantargia Expands Share Capital After Rights Issue Completion
Premium
Company Announcements
Cantargia Expands Share Capital After Rights Issue Completion
2M ago
More DE:7V3 News >

7V3 News on the Web

Cantargia Ramps Up Investor Outreach with Series of September Conferences
TipRanks News
Bullish
Cantargia schedules Q2 2026 results release and investor conference call
TipRanks News
Neutral
Cantargia: Nadunolimab’s Complementary Role in PDAC Supports Maintained Buy Rating and Reaffirmed $14 Target
TipRanks News
Bullish
Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer
TipRanks News
Bullish
Cantargia Highlights Nadunolimab’s Pancreatic Cancer Potential in Upcoming KOL Call
TipRanks News
Bullish
Cantargia: Buy Rating Reiterated on Nadunolimab Pipeline Progress and New Lung Nodule Trial; SEK14.00 Price Target Maintained
TipRanks News
Bullish
Cantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients
TipRanks News
Bullish
Cantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DE:7V3
Sector Average
Media Buzz
This Week1 articles
Weekly Average0.25 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:7V3’s Media Buzz Sentiment?
1 articles about DE:7V3 were published this week. In an average week, 0.25 articles are published.
    What is DE:7V3’s weekly average amount of articles?
    In an average week, 0.25 articles about DE:7V3 are published.
      What is DE:7V3’s News Sentiment?
      100% of articles about DE:7V3 were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        BAYRYBayer
        ABTAbbott Laboratories
        INCYIncyte
        SMMTSummit Therapeutics
        CRVOCervoMed
        Showing the stocks with the most bullish news sentiment over the past week